It has been conventionally believed that long-acting GLP-1 receptor agonists, such as exenatide QW and liraglutide, are much more effective in targeting fasting, rather than postprandial, hyperglycemia and have little, if any, effect on gastric emptying. Here, GLP1R is linked to Hyperglycemia.